| Overview |
| bs-11173R-Cy3 |
| NARF Polyclonal Antibody, Cy3 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse |
| Human, Rat, Dog, Cow, Sheep, Horse |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human NARF |
| 1-100/456 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Nucleus |
| DKFZp434G0420; FLJ10067; GC17P078009; IOP2; Iron only hydrogenase like protein 2; Nuclear prelamin A recognition factor; Prenyl dependent prelamin A binding NARF_HUMAN. |
| Prenylation and methylation are two forms of protein modification, both of which are important for a variety of functions, including membrane attachment, protein-protein interactions and signaling events. NARF (nuclear prelamin A recognition factor), also known as IOP2, is a 456 amino acid nuclear protein that belongs to the NARF family. Expressed ubiquitously with highest expression in heart, skeletal muscle and brain, NARF binds to the C-terminal end of prenylated prelamin A and may be a member of a prelamin A-containing endoprotease complex. Additionally, via its association with prelamin A, NARF may be involved in heterochromatin organization. NARF is expressed as three isoforms due to alternative splicing events and, upon DNA damage, may be phosphorylated by ATM or ATR. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz